- In November 2023, Valenva received approval from the U.S. Food and Drug Administration (FDA) for its chikungunya vaccine, IXCHIQ, marking a significant breakthrough in the battle against Chikungunya fever. This approval signals a promising remedy for curbing the virus's spread among individuals aged 18 years and above. Following this, the U.S. Advisory Committee on Immunization Practices (ACIP) endorsed guidelines for the vaccine's administration in specific demographics, underscoring its pivotal role in preventing Chikungunya infections. This recent development represents a crucial stride in public health endeavors aimed at tackling the global impact of Chikungunya fever
- In November 2023, Valneva SE received accelerated approval in the EU for its Chikungunya vaccine candidate VLA1553, marking a major advancement in preventive treatment. This development is expected to influence market dynamics positively by offering a long-term immunization option in endemic regions.
